FATE
$1.16-0.00 (-0.43%)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...
Recent News
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company’s clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside chat hosted by Leerink Partners senior equity research analyst Daina Graybosch. Valamehr emphasized that
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 27 cents. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for a loss of 27 cents per share.
Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?